Riederer P, Wuketich S. A detailed study of influential factors in human brain amine analysis[J]. Neural Transm, 1976, 38(34): 277-301.
[2]
Berg D. Transcranial ultrasound as a risk marker for Parkinson′s disease[J]. Mov Disord, 2009, 24(2): 677-683.
[3]
Becker G, Seufert J, Bogdahn U, et al. Degeneration of substantia nigra in chronic Parkinson′s disease visualized by transcranial-color-coded real-time sonography[J]. Neurology, 1995, 45(1): 182-184.
[4]
Berg D. In vivo detection of iron and neuromelanin by transcranial sonography-a new approach for early detection of substantia nigra damage[J]. Neural Transm, 2006, 113(6): 775-780.
[5]
Berg D, Godau J, Walter U. Transcranial sonography in movement disorders[J]. Lancet Neurol, 2008, 7(11): 1044-1055.
[6]
Walter U, Dressler D, Wolters A, et al. Transcranial brain sonography fndings in clinical subgroups of idiopathic Parkinson′s disease[J]. Mov Disord, 2007, 22(1): 48-54.
[7]
Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson′s disease and its relation to clinical fndings[J]. Neurol, 2001, 248(8): 684-689.
[8]
Skoloudik D, Bartova P, Herzog R. Trancranial sonography in Parkinson′s disease[J]. Aging Health, 2009, 5(1): 43-49.
[9]
Okawa M, Miwa H, Kajimoto Y, et al. Transcranial sonography of the substantia nigra in Japanese patients with Parkinson′s disease oratypical parkinsonism: clinical potential and limitations[J]. Intern Med, 2007, 46 (18): 1527-1530.
[10]
Becker G, Seufert J, Bogdahn U, et al. Degeneration of substantia nigra in chronic Parkinson′s disease visualized by transcranial color-coded real-time sonography[J]. Neurology, 1995, 45(1): 182-184.
[11]
Gaenslen A, Unmuth B, Godau J, et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson′sdisease: a prospective blinded study[J]. Lancet Neurol, 2008, 7(5): 417-424.
[12]
Berg D, Merz B, Reiners K, et al. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson′s disease[J]. Mov Disord, 2005, 20(4): 383-388.
[13]
Berg D, Siefker C, Ruprecht-Dorfler P, et al. Relationship of substantia nigra echogenicity and motor function in elderly subjects[J]. Neurology, 2001, 56(1): 13-17.
[14]
Behnke S, Double KL, Duma S, et al. Substantia nigra echomorphology in the healthy very old: correlation with motor slowing[J]. Neuroimage, 2007, 34(11): 1054-1055.
[15]
Ruprecht-Dorfler P, Berg D, Tucha O, et al.Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson′s Disease[J]. Neuroimage, 2003, 18(4): 416-422.
[16]
Walter U, Wittstock M, Benecke R, et al. Substantia nigraechogenicity is normal in non-extrapyramidal cerebral disordersbut increased in Parkinson′s disease[J]. Neural Transm, 2002, 109(2): 191-196.
[17]
Berg D, Roggendorf W, Schroder U, et al. Echogenicity of the substantia nigra: associationwith increased iron content and marker for susceptibility to nigrostriatal injury[J]. Arch Neurol, 2002, 59(10): 999-1005.
[18]
Berg D, Becker G, Zeiler B, et al. Vulnerability of the nigrostriatal system asdetected by transcranial ultrasound[J]. Neurology, 1999, 53(11): 1026-1031.
[19]
Budisic M, Trkanjec Z, Bosnjak J, et al. Distinguishing Parkinson′s disease and essential tremor with transcranial Sonography[J]. Acta Neurol Scand, 2009, 119(1): 17-21.
Behnke S, Berg D, Naumann M, et al. Differentiation of Parkinson′sdisease and a typical Parkinsonian syndromes by transcranial ultrasound[J]. Neurol Neurosurg Psychiatry, 2005, 76(4): 423-425.
[23]
Berg D. Ultrasound in the (premotor) diagnosis of Parkinson′s disease[J]. Parkinsonism Relat Disord, 2007, 13(4): 429-433.
[24]
Walter U, Niehaus L, Probst T, et al. Brain parenchyma sonography discriminates Parkinson′s disease and atypical Parkinsonian syndromes[J]. Neurology, 2003, 60(1): 74-77.
[25]
Walter U, Dressler D, Wolters A, et al. Sonographic discrimination of dementia with Lewy bodies and Parkinson′s disease with dementia[J]. Neurol, 2006, 253(5): 448-454.
[26]
Hochstrasser H, Tomiuk J, Walter U, et al. Functional relevance of ceruloplasmin mutations in Parkinsonism disease[J]. FASEBJ, 2005, 19(20): 185l-1853.
[27]
Bouwmans AE, Vlaar AM, Srulijes K, et al. Transcranial sonography for the discrimination of idiopathic Parkinson′s disease from the atypical parkinsonian syndromes[J]. Int Rev Neurobiol, 2010, 90(1): 121-146.
[28]
Zecea L, Berg D, Arzberger T,et al. in vivo detection of iron and neuromelanin by trameranial sonographya new approach for eayly detection of substantia nigra damage[J]. Mov Disord, 2005, 20(12): 1278-1285.
[29]
Berg D, Hochstrasser H, Schweitzer KJ, et al. Disbance of iron metabolism in Parkinson′s disease: ultrasonography as a biomarker[J]. Neurotox Res, 2006, 9(1): 1-13.
[30]
Akbas N, Hochstrasser H, Deplazes J, et al. Screening formutations of the HFE gene in Parkinson′s disease patients with hyperechogenicity of the substantia nigra[J]. Neurosci Lett, 2006, 407(1): 16-19.
[31]
Lova G, Garmashov A, Andxouchtchenko N, et al. Postnatal decrease in substaraia nigra echogenicity: implications for the pathogenesis of Parkinson′s disease[J]. Neurol, 2004, 251(13): 1451-1454.
[32]
Walter U, Behnke S, Eyding J, et al. Transcranial brain parenchyma sonography in movement disorders: state of the art [J].Ultrasound Med Biol, 2007, 33(1): 15-25.
[33]
Tsai CF, Wu RM, Huang YW, et al. Transcranial color-coded sonography helps differentiation between idiopathic Parkinson′s disease and vascular Parkinsonism[J]. Neurol, 2007, 254(5): 501-508.
